Targeted protein degraders do not simply occupy a disease protein and block its activity. They recruit the cell’s disposal machinery to remove it, potentially opening targets conventional drugs cannot reach.
Molecular glue funding is back, but clinic data remain thin. Degron’s HuR bet now faces the proof burden in solid tumors.
Discover how Amphista Therapeutics’ SMARCA2 and TEAD degrader data could redefine targeted cancer therapies. Read the full analysis now.
Orum Therapeutics unveiled AACR 2026 data for ORM-1153 in AML. Read why the CD123 degrader strategy could matter for efficacy and tolerability.
Triana Biomedicines launches TRI-611 trial in ALK lung cancer. Can molecular glue degraders overcome resistance? Read the full analysis.
Orum Therapeutics presents ORM-1153 DAC preclinical data at AACR 2026, including primate safety findings ahead of a planned AML IND filing. Read the analysis.
FDA accepts Bristol Myers Squibb’s iberdomide NDA for relapsed multiple myeloma. Find out what this CELMoD filing could change next.